Fluxergy
Fluxergy is a privately held Irvine-based diagnostics company that has developed a single benchpoint-of-care analyzer combining PCR, immunochemistry, clinical chemistry, and cytometry on one platform, serving human healthcare, equine veterinary, and OEM assay development markets.
- Company typePrivate
- Founded2013
- HeadquartersIrvine, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Fluxergy does
Fluxergy is a privately held medical diagnostics company founded in 2013 and headquartered in Irvine, California, that develops a multimodal point-of-care (POC) testing platform. The platform combines four diagnostic modalities—molecular (PCR), immunochemistry, clinical chemistry, and cytometry—on a single benchtop analyzer (the Fluxergy Analyzer) using modular microfluidic test cards and a proprietary middleware software called Fluxergy Works. This architecture enables sample-to-answer workflows with results delivered in under one hour for molecular assays and approximately five minutes for chemistry panels such as the Basic Metabolic Panel (BMP), replacing the need for multiple dedicated instruments in clinical and veterinary settings.
The company operates a three-pillar revenue model: (1) hardware sales of the Fluxergy Analyzer to healthcare and veterinary customers, (2) recurring revenue from proprietary test card consumables, with current manufacturing capacity of 1.2 million cards annually and stated scalability to 12 million, and (3) an OEM platform licensing model where assay developers retain IP and regulatory ownership while paying Fluxergy for hardware and software access. Go-to-market is executed through direct sales in the United States (with dedicated human diagnostics and equine veterinary specialists), through Fluxergy Europe GmbH in Germany for European distribution, and through OEM development partners globally. Customer segments are organized vertically into Human Health/Clinical Diagnostics, Equine Veterinary Medicine (currently the most evidenced segment with multiple named accounts), and OEM Development Partners.
Fluxergy has raised approximately $50 million across four disclosed funding rounds since 2013, with the most recent $30 million round in May 2020 led by John Tu. The company received CE-IVD marking for its one-hour COVID-19 RT-PCR test in March 2021, enabling European market entry, and has continued to expand through partnerships with NIAID (2024), ACESO (2024), and an asset acquisition from InnaMed Inc. in 2025 to extend its clinical chemistry capabilities.
Fluxergy firmographics
Firmographics- Name
- Fluxergy
- Legal name
- Fluxergy Inc.
- Website
- https://fluxergy.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Fluxergy is a privately held Irvine-based diagnostics company that has developed a single benchpoint-of-care analyzer combining PCR, immunochemistry, clinical chemistry, and cytometry on one platform, serving human healthcare, equine veterinary, and OEM assay development markets.
- Ownership category
- akta.pro rank
Fluxergy industry classification
Industry- Product category
- Point-of-Care Diagnostic Equipment
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Veterinary Services (54194), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)
Keywords
Where Fluxergy is headquartered
LocationHeadquarters
- HQ city
- Irvine
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Fluxergy business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Hardware Sales: Sale of Fluxergy Analyzer instruments to healthcare facilities, veterinary practices, and OEM partners.
- Test Card Consumables: Recurring revenue from sale of proprietary test cards (consumables) for use with the Fluxergy Analyzer. Manufacturing capacity of 1.2MM test cards annually, scalable to 12MM.
- OEM Platform Licensing: Partners develop and commercialize their own assays on the Fluxergy platform. Partners retain IP and regulatory ownership for their assays while paying for platform access and manufacturing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom enterprise pricing based on volume and contract terms |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels7 records
Fluxergy product offering
Product offeringCore offering
Fluxergy develops and manufactures a multimodal point-of-care diagnostic platform consisting of the Fluxergy Analyzer (benchtop instrument), Fluxergy Test Cards (modular consumables), and Fluxergy Works (cloud-connected middleware software). The platform integrates four diagnostic modalities—molecular (PCR), immunochemistry, clinical chemistry, and cytometry—on a single instrument, serving human health and equine veterinary markets with sample-to-answer workflows delivering results in under one hour.
Product overview
Fluxergy offers an integrated multi-modal point-of-care diagnostic platform consisting of the Fluxergy Analyzer (benchtop instrument), Fluxergy Test Cards (modular consumables), and Fluxergy Works software (middleware/connectivity). The platform supports four distinct testing modalities: Molecular (PCR), Immunochemistry, Clinical Chemistry, and Cytometry—all running on a single analyzer. The product portfolio includes both CE-IVD cleared assays (COVID-19 PCR, HVRe Respiratory Panel) and veterinary assays (Equine Multiplex Reagents, Streptococcus equi, EHV-1, Environmental Salmonella), with a development pipeline including Basic Metabolic Panel, Comprehensive Metabolic Panel, and CBC. Fluxergy operates an open platform model allowing OEM partners to develop and commercialize their own assays on the system.
Differentiator
Problem solved
Functional benefit
Brands
- Fluxergy Analyzer: The benchtop diagnostic analyzer that runs molecular, immunoassay, clinical chemistry, and cytometry tests
- Fluxergy Test Cards
- Fluxergy Works
Products and services
- Fluxergy Analyzer Benchtop diagnostic analyzer that runs molecular assays, immunoassays, clinical chemistry tests, and cytometry tests using fluorescence, colorimetric, electrical potentiometry, and imaging cytometry sensor and fluidics systems. Features a pneumatic fluidic system with six independently controlled channels, area sensor-based optical system using standard CMOS sensors, and custom in-house developed modular electrical motherboard.
- Fluxergy Test Cards Modular microfluidic chip-based test cards with configurable zones depending on technology required. Supports multiple PCR tests with 12+ markers, immunochemistry panels with 12+ markers, clinical chemistry panels with 12+ markers, multiplex cytometry, and multimodal test cards with up to 30 markers.
- Fluxergy Works Proprietary middleware software providing an intuitive user interface to set up, manage, and run Fluxergy Analyzers. Features HIPAA-compliant cloud connectivity with encryption, AI-powered preventative maintenance, fleet management, and seamless EMR/LIMS integration. Assay Modules enable adding new test modalities by loading a file without patches.
- HVRe Influenza / RSV / SARS-CoV-2 Respiratory Panel Multiplex respiratory panel using real-time PCR technology that detects and differentiates between influenza A/B, RSV, and SARS-CoV-2. Delivers results in 75 minutes with room-temperature stable reagents.
- COVID-19 PCR Test Kit Rapid point-of-care PCR test detecting SARS-CoV-2 virus in 65 minutes with 99.64% variant detection coverage. RNA extraction not required; allows sample pooling up to 10 samples. CE-IVD marked.
- Streptococcus equi subsp. equi PCR Reagent PCR-based assay detecting the SeM/eqbE gene from equine samples for identification of Strangles disease. Provides results in 1 hour with minimal hands-on time. Designed for equine veterinary practices managing strangles outbreaks.
- Equine Herpesvirus 1 (EHV-1) PCR Reagent PCR assay detecting the gB/gD gene for identification of EHV-1 in horses. Important for respiratory and neurological disease detection in equine populations.
- Environmental Salmonella PCR Test Kit Environmental biosurveillance test detecting Salmonella in veterinary hospital settings. Delivers results in under 1 hour after 16-24 hour incubation, improving biosecurity and stall turnover.
- Equine Multiplex Reagents A 4-in-1 multiplex reagent targeting EHV-1, EHV-4, EIV (Equine Influenza Virus), and S. equi subsp. equi genes. Temperature-stable reagents with simplified dropper bottle workflow.
Quantifiable outcome
- Turnaround time reduced from 1-3 days to 1 hour for equine infectious disease testing
- +5 more outcomes
Companies that use Fluxergy
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles3 records
Fluxergy technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Fluxergy partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- National Institute of Allergy and Infectious Diseases (NIAID)coreFluxergy announced collaboration with NIH's NIAID. This represents a significant strategic partnership for the development of diagnostic solutions targeting infectious diseases.
- Austere environments Consortium for Enhanced Sepsis Outcomes (ACESO)coreFluxergy announced partnership with ACESO for sepsis detection testing development. ACESO focuses on developing diagnostics for austere and resource-limited environments.
- SMARTmedSolutionsminorPartnership spotlight featuring SMARTmedSolutions collaboration with Fluxergy.
- Solis BioDynecorePartnership spotlight: Solis BioDyne tested their SOLISFast DNA Polymerase PCR Master Mixes on the Fluxergy point-of-care system. Successfully validated reagent efficacy while Fluxergy imported OEM partner's testing assay to Fluxergy Works platform.
- Wyss Diagnostics AcceleratorcoreFluxergy joined the Wyss Diagnostics Accelerator's Industrial Participant Program as an inaugural member. The Wyss Institute focuses on developing breakthrough diagnostics technologies.
- Mass General BrighamcoreMass General Brigham partnered with Fluxergy to evaluate rapid COVID-19 molecular testing system. Major healthcare system collaboration for clinical validation.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
Fluxergy competitors and assessment
Company assessmentDirect peers
- Cepheid (Danaher): Cepheid's GeneXpert system is the gold-standard molecular POC platform offering PCR-based diagnostics (including multiplex respiratory and infectious disease panels) at the point of care. Directly competes with Fluxergy's PCR and respiratory menu, with far deeper hospital penetration and FDA-cleared assay menu.
- bioMérieux (BioFire): BioFire's FilmArray multiplex PCR system is a leading syndromic molecular POC platform used in hospital and physician office labs. Competes directly with Fluxergy's multiplex PCR respiratory and infectious disease panels.
Broad incumbents
- Abbott: Abbott's ID NOW (molecular POC) and i-STAT (chemistry/hematology POC) compete across two of Fluxergy's four modalities. As a diversified diagnostics incumbent with massive commercial reach, Abbott represents the primary large-cap competitor Fluxergy must displace to scale the human-health business.
- Roche (GenMark Diagnostics): Roche's cobas Liat and the acquired GenMark ePlex are molecular POC systems with multiplex panels. Roche's global commercial infrastructure and broad assay menu make it a key competitor as Fluxergy tries to expand beyond equine.
- QuidelOrtho: QuidelOrtho offers Sofia (immunoassay), Triage (cardiac POC), and recently acquired BioFire-adjacent molecular assets. Overlaps with Fluxergy's immunochemistry and molecular POC capabilities across clinical and physician office channels.
- IDEXX Laboratories: IDEXX is the dominant veterinary diagnostics company with reference lab services and in-clinic analyzers (Catalyst Dx, ProCyte Dx, SediVue). While primarily reference-lab-centric, IDEXX is the most logical incumbent competitor if Fluxergy tries to expand equine POC into broader companion animal diagnostics.
Emerging players
- Visby Medical: Visby Medical develops single-use PCR POC devices for infectious disease (sexual health, respiratory). Comparable to Fluxergy as a smaller, growth-stage molecular POC innovator pursuing rapid time-to-result at point of care.
- Talis Biomedical: Talis is developing a molecular POC platform (Talisman) targeting infectious disease applications. Directly comparable as a small-cap, growth-stage POC molecular diagnostics competitor to Fluxergy's PCR offering.
- T2 Biosystems: T2 Biosystems offers the T2Dx and T2Bacteria/PanCandida panels for direct-from-sample molecular detection without sample prep. Comparable to Fluxergy as an emerging molecular diagnostics platform targeting rapid clinical and sepsis decision-making.
- Mesa Labs: Mesa Labs (and its acquired Gyros Protein Technologies and related diagnostics assets) is a smaller specialty diagnostics player with overlapping POC and life-sciences reagent exposure. Comparable as a mid-size platform diagnostics peer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Fluxergy social profiles
Digital presenceFluxergy financial estimates
Financial estimateRevenue estimate
Valuation estimate
Fluxergy leadership team
Management profileNumber of profiles
Profiles4 records
Fluxergy funding detail
Funding detailFunding overview
Funding rounds4 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Fluxergy M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Fluxergy
What does Fluxergy do?
Fluxergy develops and manufactures a multimodal point-of-care diagnostic platform consisting of the Fluxergy Analyzer (benchtop instrument), Fluxergy Test Cards (modular consumables), and Fluxergy Works (cloud-connected middleware software). The platform integrates four diagnostic modalities—molecular (PCR), immunochemistry, clinical chemistry, and cytometry—on a single instrument, serving human health and equine veterinary markets with sample-to-answer workflows delivering results in under one hour.
Is Fluxergy a public or private company?
Fluxergy is a private company. It is classified as venture growth investor backed and is currently operating.
When was Fluxergy founded?
Fluxergy was founded in 2013. It employs 51 to 100 people.
Where is Fluxergy based?
Fluxergy is headquartered in Irvine, United States, in the North America region.
How does Fluxergy make money?
Three revenue lines are on record. Hardware Sales are the primary driver. The others are test Card Consumables and OEM Platform Licensing.
Who are Fluxergy's main competitors?
Direct peers on record are Cepheid (Danaher) and bioMérieux (BioFire). Broad incumbents are Abbott, Roche (GenMark Diagnostics), QuidelOrtho and IDEXX Laboratories. Emerging players are Visby Medical, Talis Biomedical, T2 Biosystems and Mesa Labs.
Does Fluxergy have an API?
No public API is recorded for Fluxergy.
What industry is Fluxergy in?
Fluxergy's product category is Point-of-Care Diagnostic Equipment. Its primary akta.pro industry code is HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices). Its NAICS code is 621511 and its SIC code is 2835.